Treatment Update in Multiple Sclerosis
Multiple sclerosis is the most common cause of disability in young people in the Western world. Reduced life expectancy and worsening quality of life due to increasing disability later in the disease course have significant personal and societal costs. Changes in treatment strategies and newly available treatments hope to improve the outlook for our often young patients. This paper details currently available treatments and some that are expected to reach the market shortly.
KeywordsMultiple sclerosis Treatment Algorithm Interferon-beta Glatiramer acetate Natalizumab Mitoxantrone Fingolimod Dimethyl fumarate Cladribine Alemtuzumab Rituximab
Dr. Morris has had travel/accommodations expenses covered/reimbursed by UCB.
Dr. Yiannikas has received grant support from Biogen Idec and Novartis; has received honoraria for giving lectures from Biogen Idec and Novartis; and has had travel/accommodations expenses covered/reimbursed by Biogen Idec, Novartis, and Sanofi Aventis.
Papers of particular interest, published recently, have been highlighted as • Of importance •• Of major important
- 6.• Howell ORN, Nicholas R, Carassiti D, Roncaroli F, Magliozzi R, Aloisi F, et al. Oral Presentation 105 in Abstracts of the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis. October 19–22, 2011. Amsterdam, The Netherlands. Mult Scler. 2011;17(10 Suppl):S9–524. This describes nodules of inflammation sequestered in the meninges, which may be a locus for the chronic immunomodulation–resistant progressive phase of the disease.CrossRefGoogle Scholar
- 9.Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9700):1503–11.PubMedCrossRefGoogle Scholar
- 11.Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, Smith S, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9444):1489–96.PubMedCrossRefGoogle Scholar
- 12.Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009;8(11):987–97.PubMedCrossRefGoogle Scholar
- 13.• Goodin DS, Traboulsee A, Knappertz V, Reder AT, Li D, Langdon D, et al. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(3):282–7. This article provides long-term follow-up data with regard to early versus delayed treatment initiation and early indicators of disease course.PubMedCrossRefGoogle Scholar
- 19.Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7(10):903–14.PubMedCrossRefGoogle Scholar
- 22.• Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8(3):254–60. This was the first group to describe a combined radiological and clinical outcome parameter to guide future trial design and retrospective analysis.PubMedCrossRefGoogle Scholar
- 25.•• Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 2011;10(8):745–58. PML risk stratification is essential in informing treatment decision making in patients with active disease. This article presents the data and an algorithm to assist treatment plans.PubMedCrossRefGoogle Scholar
- 27.•• Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401. This was the trial that led to marketing of the first oral therapy available for multiple sclerosis treatment.PubMedCrossRefGoogle Scholar
- 30.• Lindsey J, Haden-Pinneri K, Memon N, Buja L. Sudden unexpected death on fingolimod. Mult Scler. 2012 Feb 2. Concerns around cardiac death in fingolimod are emerging, and this is the first published information on a case. Google Scholar
- 33.• Martinelli V, Cocco E, Capra R, Salemi G, Gallo P, Capobianco M, et al. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology. 2011;77(21):1887–95. Mitoxantrone is still used in some countries. This paper describes that the risk of hematologic malignancies may be more common and for longer than previously realized.PubMedCrossRefGoogle Scholar
- 38.Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sorensen PS, Vermersch P, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 2011;10(4):329–37.PubMedCrossRefGoogle Scholar
- 39.• O’Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293–303. This provides information on a potential new oral agent for treatment of multiple sclerosis.PubMedCrossRefGoogle Scholar
- 40.Confavreux C, Li DK, Freedman MS, Truffinet P, Benzerdjeb H, Wang D, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler. 2012 Feb 7.Google Scholar
- 41.Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372(9648):1463–72.PubMedCrossRefGoogle Scholar
- 42.•• Gold RKL, Bar-Or A, Arnold D, Giovannoni G, Selmaj K, Yang M, et al. Oral presentation 95 in Abstracts of the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis. October 19–22, 2011. Amsterdam, The Netherlands. Mult Scler. 2011;17(10 Suppl):S9–524. Key data are presented on a phase 3 trial of dimethyl fumarate. The full data are expected to be published shortly. Efficacy and safety appear more promising than previously suspected.CrossRefGoogle Scholar
- 44.• Selmaj KGR, Kappos L, Bar-Or A, Arnold DL, Giovannoni G, Sweetser M, Novas M, Raghupathi K, Sheikh SI, Dawson KT. Poster 994 Safety and Tolerability of BG-12 in the Phase 3 DEFINE Trial in Patients with Relapsing-Remitting Multiple Sclerosis. 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis October 19–22, 2011 [serial on the Internet]. http://www.posters2view.com/ECTRIMS2011/numindex.php accessed 28 Feb 2012. Key data are presented on a phase 3 trial of dimethyl fumarate. The full data are expected to be published shortly. Efficacy and safety appear more promising than previously suspected.
- 46.•• D’Haeseleer M, Cambron M, Vanopdenbosch L, De Keyser J. Vascular aspects of multiple sclerosis. Lancet Neurol. 2011;10(7):657–66. This is a comprehensive discussion of the vascular aspects of multiple sclerosis and evidence to assist in discussion with patients regarding unproven interventions.PubMedCrossRefGoogle Scholar
- 49.• Hartung HP, Montalban X, Sorensen PS, Vermersch P, Olsson T. Principles of a new treatment algorithm in multiple sclerosis. Expert Rev Neurother. 2011;11(3):351–62. This article shares a view on the next phase of developing treatment algorithms in an increasingly complex treatment environment.PubMedCrossRefGoogle Scholar